Sequent Scientific, 512529, SEQUENT Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

5,363.57
67.63
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

5,618.39
N/A
7.17

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

14.22
13.54
4.59

EBITDA CAGR (%)

10 Years
5 Years
3 Years

14.11
24.60
8.84

PAT CAGR (%)

10 Years
5 Years
3 Years

2.97
15.48
-45.06

P:E (Median)

8 Years
5 Years
3 Years

-
4.21
30.73

P:BV (Average)

8 Years
5 Years
3 Years

7.40
3.12
2.95

EV:EBITDA (Average)

8 Years
5 Years
3 Years

57.44
26.89
15.88

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Sep 20 Sep 19 Var% Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var%
Net Sales 69.64 51.52 35.17% 59.24 51.72 14.54% 62.29 55.59 12.05% 61.80 48.14 28.38%
Expenses 59.17 48.72 21.45% 49.46 48.68 1.60% 51.76 53.11 -2.54% 55.84 46.68 19.62%
EBITDA 10.47 2.80 273.93% 9.79 3.04 222.04% 10.54 2.48 325.00% 5.96 1.46 308.22%
EBIDTM 15.03% 5.43% 16.52% 5.87% -0.29% 4.46% 9.65% 3.03%
Other Income 6.10 7.26 -15.98% 2.27 2.03 11.82% 3.05 1.61 89.44% 2.11 3.02 -30.13%
Interest 0.73 1.19 -38.66% 1.10 1.42 -22.54% 1.23 1.83 -32.79% 1.19 1.32 -9.85%
Depreciation 2.16 2.23 -3.14% 2.16 2.23 -3.14% 2.31 2.26 2.21% 2.19 2.30 -4.78%
PBT 11.03 6.64 66.11% 8.80 1.42 519.72% 10.06 0.01 100,500.00% 4.69 0.87 439.08%
Tax 1.82 -3.54 - 1.87 0.00 0 3.24 -1.38 - 1.77 0.00 0
PAT 9.21 10.18 -9.53% 6.92 1.42 387.32% 6.82 1.39 390.65% 2.92 0.87 235.63%
PATM 13.23% 19.77% 11.69% 2.75% 2.87% 2.50% 4.72% 1.80%
EPS 0.37 0.41 -9.76% 0.28 0.06 366.67% 0.27 0.06 350.00% 0.12 0.03 300.00%

Description Sep 20 Sep 19 Var% Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var%
Net Sales 346.27 284.22 21.83% 310.26 278.02 11.60% 300.58 281.90 6.63% 316.42 270.53 16.96%
Expenses 289.88 247.06 17.33% 259.25 239.57 8.21% 255.85 242.91 5.33% 266.44 234.84 13.46%
EBITDA 56.39 37.16 51.75% 51.02 38.44 32.73% 44.74 39.00 14.72% 49.98 35.69 40.04%
EBIDTM 16.29% 13.07% 16.44% 13.83% 14.01% 13.83% 15.80% 13.19%
Other Income 2.64 5.97 -55.78% 1.55 1.31 18.32% 1.83 2.43 -24.69% 0.98 1.99 -50.75%
Interest 7.36 7.84 -6.12% 7.65 8.95 -14.53% 9.33 8.90 4.83% 9.60 8.35 14.97%
Depreciation 13.30 12.46 6.74% 13.03 12.01 8.49% 13.09 10.92 19.87% 13.05 11.16 16.94%
PBT 29.32 22.83 28.43% 31.89 18.80 69.63% 24.14 21.60 11.76% 28.31 18.17 55.81%
Tax 7.96 -1.64 - 7.42 3.50 112.00% 5.91 0.28 2,010.71% 4.25 2.60 63.46%
PAT 21.36 24.47 -12.71% 24.47 15.30 59.93% 18.23 21.32 -14.49% 24.06 15.57 54.53%
PATM 6.17% 8.61% 7.89% 5.50% 7.11% 7.56% 7.60% 5.76%
EPS 0.86 0.86 0.00% 0.84 0.46 82.61% 28.29 0.69 4,000.00% 0.82 0.53 54.72%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 252.97 227.33 166.26 271.20 105.87 394.59 444.82 445.08 235.77 332.43 277.98 Net Sales Growth 22.23% 36.73% -38.69% 156.16% -73.17% -11.29% -0.06% 88.78% -29.08% 19.59% Cost Of Goods Sold 584.64 113.04 94.62 161.37 72.47 218.33 229.86 245.55 133.20 190.11 140.26 Gross Profit -331.67 114.29 71.64 109.83 33.40 176.26 214.95 199.53 102.57 142.32 137.72 GP Margin -131.11% 50.27% 43.09% 40.50% 31.55% 44.67% 48.32% 44.83% 43.50% 42.81% 49.54% Total Expenditure 216.23 205.10 163.57 258.06 121.27 359.06 384.54 437.81 253.85 296.96 231.01 Power & Fuel Cost - 12.73 8.52 2.32 2.14 17.98 20.68 21.77 17.98 20.21 15.68 % Of Sales - 5.60% 5.12% 0.86% 2.02% 4.56% 4.65% 4.89% 7.63% 6.08% 5.64% Employee Cost - 17.10 10.71 25.12 17.90 38.84 45.47 42.87 29.10 25.44 22.70 % Of Sales - 7.52% 6.44% 9.26% 16.91% 9.84% 10.22% 9.63% 12.34% 7.65% 8.17% Manufacturing Exp. - 51.52 41.13 15.87 14.85 56.50 48.54 49.63 34.33 26.30 28.23 % Of Sales - 22.66% 24.74% 5.85% 14.03% 14.32% 10.91% 11.15% 14.56% 7.91% 10.16% General & Admin Exp. - 8.55 7.15 13.02 9.92 15.19 23.99 41.71 14.93 10.56 16.58 % Of Sales - 3.76% 4.30% 4.80% 9.37% 3.85% 5.39% 9.37% 6.33% 3.18% 5.96% Selling & Distn. Exp. - 2.11 1.04 0.83 0.47 4.03 5.71 7.90 7.03 9.12 7.21 % Of Sales - 0.93% 0.63% 0.31% 0.44% 1.02% 1.28% 1.77% 2.98% 2.74% 2.59% Miscellaneous Exp. - 0.04 0.40 39.53 3.53 8.19 10.29 28.37 17.28 15.22 7.21 % Of Sales - 0.02% 0.24% 14.58% 3.33% 2.08% 2.31% 6.37% 7.33% 4.58% 0.12% EBITDA 36.76 22.23 2.69 13.14 -15.40 35.53 60.28 7.27 -18.08 35.47 46.97 EBITDA Margin 14.53% 9.78% 1.62% 4.85% -14.55% 9.00% 13.55% 1.63% -7.67% 10.67% 16.90% Other Income 13.53 14.56 13.96 24.67 19.07 15.55 3.56 5.25 2.92 11.33 11.41 Interest 4.25 5.04 3.22 4.54 0.42 16.44 47.46 38.74 24.64 28.27 20.04 Depreciation 8.82 8.95 7.22 14.37 3.25 24.18 26.38 27.13 23.00 21.03 17.18 PBT 34.58 22.81 6.20 18.90 -0.01 10.46 -9.99 -53.34 -62.81 -2.50 21.16 Tax 8.70 1.47 -1.38 2.87 0.00 0.07 1.70 0.00 -8.31 -3.96 6.28 Tax Rate 25.16% 6.44% -22.26% 0.70% 0.00% 0.67% 3.95% 0.00% 13.23% 158.40% 28.28% PAT 25.87 21.34 7.59 406.41 -0.01 10.39 41.31 -114.42 -54.50 1.47 15.93 PAT before Minority Interest 25.87 21.34 7.59 406.41 -0.01 10.39 41.31 -114.42 -54.50 1.47 15.93 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 10.23% 9.39% 4.57% 149.86% -0.01% 2.63% 9.29% -25.71% -23.12% 0.44% 5.73% PAT Growth 86.65% 181.16% -98.13% - - -74.85% - - - -90.77% EPS 1.04 0.86 0.31 16.36 0.00 0.42 1.66 -4.61 -2.19 0.06 0.64

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 1,273.53 1,179.24 1,039.31 1,030.59 683.57 624.98 465.36 455.46 326.86 345.81 311.89 Net Sales Growth 14.25% 13.46% 0.85% 50.77% 9.37% 34.30% 2.17% 39.34% -5.48% 10.88% Cost Of Goods Sold 5,145.99 605.05 543.01 554.23 356.70 311.71 240.72 243.65 181.72 192.27 162.01 Gross Profit -3,872.46 574.19 496.30 476.36 326.87 313.27 224.65 211.81 145.14 153.53 149.87 GP Margin -304.07% 48.69% 47.75% 46.22% 47.82% 50.12% 48.27% 46.50% 44.40% 44.40% 48.05% Total Expenditure 1,071.42 1,008.92 914.37 919.10 643.03 568.27 444.87 438.68 342.51 308.74 266.39 Power & Fuel Cost - 24.73 23.06 14.66 12.77 26.51 23.32 22.06 23.53 20.21 16.75 % Of Sales - 2.10% 2.22% 1.42% 1.87% 4.24% 5.01% 4.84% 7.20% 5.84% 5.37% Employee Cost - 165.06 145.95 132.07 106.22 88.62 62.39 48.12 41.47 29.40 29.82 % Of Sales - 14.00% 14.04% 12.81% 15.54% 14.18% 13.41% 10.57% 12.69% 8.50% 9.56% Manufacturing Exp. - 83.24 77.73 59.07 57.63 72.14 54.31 52.30 41.42 27.88 33.72 % Of Sales - 7.06% 7.48% 5.73% 8.43% 11.54% 11.67% 11.48% 12.67% 8.06% 10.81% General & Admin Exp. - 56.37 58.35 70.92 48.60 36.44 33.79 43.58 23.96 13.69 15.95 % Of Sales - 4.78% 5.61% 6.88% 7.11% 5.83% 7.26% 9.57% 7.33% 3.96% 5.11% Selling & Distn. Exp. - 45.16 36.29 36.87 28.78 17.46 20.27 12.30 10.51 9.23 7.52 % Of Sales - 3.83% 3.49% 3.58% 4.21% 2.79% 4.36% 2.70% 3.22% 2.67% 2.41% Miscellaneous Exp. - 29.32 29.98 51.29 32.34 15.40 10.07 16.66 19.91 16.05 7.52 % Of Sales - 2.49% 2.88% 4.98% 4.73% 2.46% 2.16% 3.66% 6.09% 4.64% 0.20% EBITDA 202.13 170.32 124.94 111.49 40.54 56.71 20.49 16.78 -15.65 37.07 45.50 EBITDA Margin 15.87% 14.44% 12.02% 10.82% 5.93% 9.07% 4.40% 3.68% -4.79% 10.72% 14.59% Other Income 7.00 10.09 8.67 17.20 11.08 14.30 9.96 3.84 4.96 10.48 6.69 Interest 33.94 35.71 32.80 39.70 28.34 38.56 44.37 39.04 33.45 29.99 23.80 Depreciation 52.47 50.62 41.92 53.30 40.07 46.22 32.94 32.60 28.61 22.98 20.69 PBT 113.66 94.08 58.88 35.70 -16.80 -13.77 -46.85 -51.00 -72.75 -5.41 7.69 Tax 25.54 12.03 2.01 13.46 -0.41 2.62 3.39 0.58 -8.06 -3.95 7.51 Tax Rate 22.47% 12.79% 3.41% 3.03% 2.44% -19.03% -40.50% -0.53% 11.08% 73.01% 215.80% PAT 88.12 69.91 48.66 421.57 -13.83 -18.47 -10.74 -110.49 -64.69 -1.40 -0.17 PAT before Minority Interest 80.72 82.05 56.88 430.83 -16.39 -16.39 -11.76 -110.49 -64.69 -1.46 -4.02 Minority Interest -7.40 -12.14 -8.22 -9.26 2.56 -2.08 1.02 0.00 0.00 0.06 3.85 PAT Margin 6.92% 5.93% 4.68% 40.91% -2.02% -2.96% -2.31% -24.26% -19.79% -0.40% -0.05% PAT Growth 14.95% 43.67% -88.46% - - - - - - - EPS 3.55 2.81 1.96 16.97 -0.56 -0.74 -0.43 -4.45 -2.60 -0.06 -0.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 886.22 917.79 948.62 1,257.33 1,205.88 156.92 50.25 109.45 126.71 125.55 Share Capital 49.67 49.37 48.75 48.75 47.65 30.48 26.74 23.44 21.34 21.23 Total Reserves 822.45 849.53 882.29 1,193.03 1,134.19 92.50 11.15 74.13 105.37 104.31 Non-Current Liabilities 11.50 36.20 19.01 38.28 42.08 79.95 109.66 113.91 85.77 111.68 Secured Loans 15.16 20.61 0.00 13.98 23.82 56.70 90.47 107.52 61.38 86.83 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.35 0.56 0.72 0.88 1.04 Long Term Provisions 4.09 22.30 24.39 28.88 22.84 22.97 18.70 5.68 15.27 11.52 Current Liabilities 105.24 79.87 26.69 168.71 109.89 427.45 414.42 319.83 298.94 190.96 Trade Payables 64.34 52.60 24.56 69.96 73.64 69.81 135.38 145.92 122.57 78.41 Other Current Liabilities 9.30 6.01 1.91 35.29 20.85 86.85 31.38 27.75 71.60 33.88 Short Term Borrowings 14.39 19.27 0.00 63.22 15.04 270.29 241.08 139.47 98.09 68.90 Short Term Provisions 17.22 1.99 0.21 0.24 0.36 0.51 6.58 6.70 6.68 9.77 Total Liabilities 1,002.96 1,033.86 994.32 1,464.32 1,357.85 664.32 574.33 543.19 511.42 428.19 Net Block 69.41 52.42 23.68 181.67 169.60 200.88 219.93 205.10 206.29 185.49 Gross Block 99.30 73.33 37.61 230.34 193.00 302.01 338.33 301.32 276.44 235.90 Accumulated Depreciation 29.89 20.90 13.93 48.67 23.40 101.13 118.40 96.22 70.15 50.41 Non Current Assets 879.01 946.46 853.77 1,095.85 1,056.39 421.95 333.95 321.05 293.54 264.65 Capital Work in Progress 3.72 0.03 3.12 32.26 19.97 8.93 11.12 21.51 17.57 16.44 Non Current Investment 738.95 788.16 672.67 834.62 834.87 183.11 65.04 54.57 38.81 13.56 Long Term Loans & Adv. 65.53 83.27 138.79 26.79 23.08 26.30 36.20 38.56 28.57 48.13 Other Non Current Assets 1.39 22.57 15.51 20.52 8.86 2.73 1.66 1.30 2.30 1.02 Current Assets 123.95 87.41 140.54 368.46 301.47 242.38 240.38 222.13 217.89 163.54 Current Investments 18.75 0.10 13.98 62.28 62.29 0.08 0.08 0.18 0.28 0.33 Inventories 31.42 25.33 13.83 62.53 56.19 66.88 101.25 82.67 63.11 61.47 Sundry Debtors 40.79 42.90 78.47 113.03 73.75 98.77 79.66 70.16 82.48 53.01 Cash & Bank 3.72 1.88 3.04 3.06 4.80 27.38 19.13 31.07 15.77 5.78 Other Current Assets 29.27 1.56 1.13 12.88 104.45 49.28 40.26 38.05 56.26 42.95 Short Term Loans & Adv. 25.66 15.65 30.09 114.68 86.38 30.28 36.32 32.06 50.48 41.20 Net Current Assets 18.71 7.54 113.85 199.75 191.58 -185.08 -174.04 -97.69 -81.05 -27.42 Total Assets 1,002.96 1,033.87 994.31 1,464.31 1,357.86 664.33 574.33 543.18 511.43 428.19

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 742.76 706.69 647.58 976.79 945.71 91.27 56.73 95.00 122.53 123.06 Share Capital 49.67 49.37 48.75 48.75 47.65 30.48 26.74 23.44 21.34 21.23 Total Reserves 679.00 638.43 581.25 912.49 874.01 26.85 -0.37 59.68 101.19 101.82 Non-Current Liabilities 241.56 214.75 227.13 246.20 299.72 277.55 159.23 144.35 104.79 123.22 Secured Loans 107.97 126.94 85.14 141.76 197.50 249.97 150.52 137.32 80.19 90.73 Unsecured Loans 42.09 20.90 18.40 23.38 13.82 0.35 0.56 0.72 0.88 8.46 Long Term Provisions 13.16 30.50 28.54 34.76 28.66 25.70 8.03 6.09 15.49 11.74 Current Liabilities 479.57 440.41 430.93 663.55 290.37 406.09 405.28 345.41 329.56 199.21 Trade Payables 220.38 209.35 160.49 203.04 143.94 90.94 114.59 150.91 123.94 82.61 Other Current Liabilities 92.65 87.80 106.52 259.26 83.23 107.43 56.80 35.63 75.38 37.71 Short Term Borrowings 134.36 127.36 152.41 194.70 56.04 204.31 226.60 151.76 123.34 69.09 Short Term Provisions 32.19 15.90 11.51 6.54 7.17 3.42 7.29 7.12 6.89 9.80 Total Liabilities 1,508.63 1,402.10 1,342.62 1,903.76 1,538.02 921.84 625.82 589.34 562.37 446.25 Net Block 632.23 498.14 475.97 684.33 586.48 474.43 237.59 227.26 229.76 210.76 Gross Block 818.12 638.06 581.74 789.60 643.70 596.25 369.07 330.69 305.11 264.26 Accumulated Depreciation 185.89 139.91 105.77 105.27 57.22 121.82 131.48 103.43 75.35 53.50 Non Current Assets 794.52 795.99 804.61 1,176.02 1,047.48 612.00 359.87 358.31 351.94 282.23 Capital Work in Progress 13.42 22.61 18.04 32.55 23.52 39.06 43.04 88.71 64.07 19.53 Non Current Investment 131.29 179.65 221.73 363.97 360.58 58.04 0.04 1.64 0.04 0.05 Long Term Loans & Adv. 14.40 32.27 31.01 37.51 30.35 36.01 76.06 39.28 55.77 50.87 Other Non Current Assets 3.18 63.31 57.86 57.66 46.54 4.47 3.15 1.42 2.30 1.02 Current Assets 714.11 606.12 538.01 727.74 490.54 309.84 265.94 231.04 210.42 164.02 Current Investments 40.18 0.47 17.34 64.12 66.98 0.58 0.08 0.18 0.28 0.33 Inventories 219.42 200.10 158.57 160.81 135.08 94.36 101.40 85.62 68.24 65.55 Sundry Debtors 318.76 278.25 258.35 254.62 192.39 115.44 83.54 65.81 70.41 55.45 Cash & Bank 75.83 72.04 42.45 47.40 25.30 38.46 36.21 33.00 35.88 9.17 Other Current Assets 59.92 8.51 5.25 146.31 70.80 61.01 44.71 46.44 35.62 33.52 Short Term Loans & Adv. 44.41 46.75 56.05 54.48 46.69 41.86 37.47 36.48 28.84 31.25 Net Current Assets 234.54 165.71 107.08 64.19 200.17 -96.25 -139.34 -114.37 -119.13 -35.19 Total Assets 1,508.63 1,402.11 1,342.62 1,903.76 1,538.02 921.84 625.81 589.35 562.36 446.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 30.20 73.80 -4.02 -24.04 100.02 -24.99 -42.37 -12.70 10.40 48.77 PBT 22.81 6.20 409.27 -0.01 10.46 43.01 -114.42 -62.81 -2.50 22.21 Adjustment 1.74 -2.19 -392.74 20.30 33.58 22.54 136.20 61.04 42.30 22.10 Changes in Working Capital 7.84 70.32 -21.10 -42.97 56.92 -89.22 -63.80 -11.41 -26.13 10.05 Cash after chg. in Working capital 32.39 74.34 -4.57 -22.68 100.95 -23.68 -42.01 -13.18 13.68 54.37 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -2.19 -0.54 0.55 -1.36 -0.93 -1.31 -0.35 0.48 -3.28 -5.60 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -10.38 -114.06 15.60 -46.84 -359.41 23.65 -60.82 -31.29 -41.11 -68.34 Net Fixed Assets -29.66 -32.63 221.87 -49.63 97.97 38.51 -26.62 -28.82 -41.67 -80.90 Net Investments 30.56 -101.61 210.25 0.26 -713.97 -118.07 -10.37 -15.66 -25.20 31.50 Others -11.28 20.18 -416.52 2.53 256.59 103.21 -23.83 13.19 25.76 -18.94 Cash from Financing Activity -18.01 40.34 -11.78 70.97 247.38 7.96 107.56 38.81 31.58 12.85 Net Cash Inflow / Outflow 1.81 0.07 -0.19 0.09 -12.01 6.62 4.37 -5.17 0.87 -6.71 Opening Cash & Equivalents 1.07 1.00 1.19 1.10 13.11 6.48 2.11 7.29 5.78 12.44 Closing Cash & Equivalent 2.87 1.07 1.00 1.19 1.10 13.10 6.48 2.11 7.29 5.78

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 115.33 116.02 45.24 -7.19 -0.05 -23.55 -44.78 -3.82 21.48 49.63 PBT 94.08 58.88 445.79 -16.80 -13.77 -8.37 -109.91 -72.75 -5.41 3.49 Adjustment 91.41 84.47 -313.85 123.31 83.81 35.92 133.52 65.98 46.98 36.77 Changes in Working Capital -58.30 -27.95 -77.87 -104.37 -71.46 -53.98 -67.45 2.48 -17.29 15.96 Cash after chg. in Working capital 127.18 115.40 54.06 2.14 -1.42 -26.44 -43.84 -4.28 24.27 56.22 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -11.85 0.62 -8.83 -9.33 1.37 2.89 -0.95 0.46 -2.79 -6.59 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -72.27 -67.69 7.17 -116.18 -315.83 -154.69 -79.95 -54.89 -66.78 -71.77 Net Fixed Assets -29.66 -32.63 221.87 -49.63 97.97 38.51 -26.62 -28.82 -41.67 -80.90 Net Investments 30.56 -101.61 210.25 0.26 -713.97 -118.07 -10.37 -15.66 -25.20 31.50 Others -73.17 66.55 -424.95 -66.81 300.17 -75.13 -42.96 -10.41 0.09 -22.37 Cash from Financing Activity -42.75 -20.08 -56.96 147.44 308.69 179.41 145.54 34.70 61.94 16.51 Net Cash Inflow / Outflow 0.31 28.25 -4.55 24.07 -7.19 1.17 20.80 -24.02 16.63 -5.62 Opening Cash & Equivalents 67.79 39.54 44.10 20.03 21.85 22.96 3.45 27.37 9.17 14.07 Closing Cash & Equivalent 68.10 67.79 39.54 44.10 20.03 21.83 22.96 3.45 27.37 9.17

Financial Ratios

Consolidated /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 35.11 36.41 38.20 50.95 49.61 8.07 2.83 8.33 11.88 11.82 ROA 2.10% 0.75% 33.06% 0.00% 1.03% 6.67% -20.48% -10.34% 0.31% 4.14% ROE 2.41% 0.83% 37.41% 0.00% 1.59% 51.35% -168.93% -48.60% 1.16% 13.16% ROCE 2.96% 0.99% 36.09% 0.03% 3.07% 20.15% -19.54% -10.55% 7.93% 15.27% Fixed Asset Turnover 2.66 3.00 2.05 0.52 1.65 1.45 1.45 0.85 1.35 1.48 Receivable days 66.55 132.93 127.17 310.76 77.04 70.28 58.94 113.28 71.66 62.69 Inventory Days 45.13 42.89 50.71 197.54 54.96 66.23 72.35 108.19 65.88 68.83 Payable days 103.60 86.82 78.05 239.99 74.47 102.24 128.36 197.86 122.93 105.70 Cash Conversion Cycle 8.08 88.99 99.83 268.31 57.53 34.27 2.92 23.61 14.61 25.82 Total Debt/Equity 0.04 0.05 0.00 0.07 0.04 2.77 9.23 2.72 1.75 1.40 Interest Cover 5.53 2.93 91.09 0.97 1.64 1.91 -1.95 -1.55 0.91 2.11

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 29.34 27.86 25.85 39.44 38.69 3.76 1.97 7.09 11.48 11.59 ROA 5.64% 4.14% 26.54% -0.95% -1.33% -1.52% -18.19% -11.23% -0.29% -0.97% ROE 11.58% 8.63% 54.15% -1.74% -3.35% -28.10% -201.83% -62.91% -1.19% -3.42% ROCE 12.33% 9.24% 41.28% 0.87% 2.72% 6.93% -16.09% -9.86% 6.98% 9.11% Fixed Asset Turnover 1.65 1.74 1.51 0.96 1.03 1.01 1.36 1.08 1.26 1.31 Receivable days 90.45 92.53 90.49 118.40 87.75 74.80 57.30 72.70 64.08 63.08 Inventory Days 63.56 61.85 56.34 78.37 65.41 73.58 71.75 82.12 68.11 69.36 Payable days 80.87 75.36 77.04 104.11 77.28 87.31 115.68 149.32 123.09 94.20 Cash Conversion Cycle 73.14 79.02 69.78 92.66 75.87 61.07 13.36 5.51 9.10 38.25 Total Debt/Equity 0.45 0.47 0.48 0.43 0.34 8.26 15.86 3.74 2.19 1.54 Interest Cover 3.63 2.80 12.19 0.41 0.64 0.81 -1.82 -1.18 0.82 1.15

Top Investors:

infinity holdings

unit trust of india investment advisory services limited a/c ascent india fund iii

sbi healthcare opportunities fund

mukul agrawal

iepf

Annual Reports:

News Update:

SeQuent Scientific launches Citramox LA in EU
10th Dec 2020, 14:48 PM

This new approval for SeQuent builds on the recent approvals of Tulazzin (Tulathromycin) and Halofusol (Halofuginone) in Europe
Read More
Sequent Scientific launches Halofusol Oral Solution in European countries
1st Dec 2020, 11:38 AM

The company is also planning to extend the launch to other geographies
Read More
Sequent Scientific - Quarterly Results
6th Nov 2020, 14:41 PM

Read More
Sequent Scientific completes acquisition of 40% stake in Provet
3rd Nov 2020, 10:45 AM

On completion of the said transaction, Provet has become a Wholly Owned Subsidiary of the Company
Read More

Sequent Scientific Ltd.

Pharmaceuticals & Drugs - Veterinary

BSE: 512529 | NSE: SEQUENT

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Sequent Scientific Ltd.

Pharmaceuticals & Drugs - Veterinary

BSE: 512529 | NSE: SEQUENT

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: